Inovio Pharmaceuticals Inc (INO)

[surf1944]

4:06AM Inovio Pharma's PENNVAX-G Global HIV vaccine plus MVA boost achieves 100% antigen-specific T-Cell immune responses in interim Phase I data (INO) 0.68 : Co announces that early data from a Phase I study assessing its PENNVAX-G global HIV vaccine plus a virus vector vaccine, Modified Vaccinia Ankara-Chiang Mai Double Recombinant, as a unique prime-boost preventive HIV vaccination strategy has demonstrated strong immune responses and safety. Early analysis of this initial data revealed a strong cell-mediated immune response, with CD4+ and CD8+ T cells specific for both the gag and env antigens encoded by the prime and boost agents. Significantly, anti-env CD4+ T-cell immune responses were noted in 100% (11 of 11) of evaluated subjects and CD8+ T-cell responses were noted in 45% (5 of 11) of evaluated subjects after the first MVA boost following the two DNA vaccinations. The env specific CD4+ and CD8+ T-cell response rates were noted to be 73% (8 of 11) and 45% (5 of 11) respectively after the second MVA boost.